Literature DB >> 23960187

Difference in therapeutic response between basal and nonbasal triple-negative breast cancers.

François Bertucci1, Pascal Finetti, Patrice Viens, Daniel Birnbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23960187      PMCID： PMC3780642          DOI： 10.1634/theoncologist.2013-0121

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

2.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Authors:  Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley
Journal:  N Engl J Med       Date:  2011-01-05       Impact factor: 91.245

Review 3.  Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

Authors:  Aleix Prat; Barbara Adamo; Maggie C U Cheang; Carey K Anders; Lisa A Carey; Charles M Perou
Journal:  Oncologist       Date:  2013-02-12

4.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

5.  How basal are triple-negative breast cancers?

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Benjamin Esterni; Fabienne Hermitte; Patrice Viens; Daniel Birnbaum
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

Review 6.  Targeted therapy for triple-negative breast cancer: where are we?

Authors:  Michael J Duffy; Patricia M McGowan; John Crown
Journal:  Int J Cancer       Date:  2012-06-07       Impact factor: 7.396

Review 7.  Basal breast cancer: a complex and deadly molecular subtype.

Authors:  F Bertucci; P Finetti; D Birnbaum
Journal:  Curr Mol Med       Date:  2012-01       Impact factor: 2.222

8.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Authors:  Aleix Prat; Joel S Parker; Olga Karginova; Cheng Fan; Chad Livasy; Jason I Herschkowitz; Xiaping He; Charles M Perou
Journal:  Breast Cancer Res       Date:  2010-09-02       Impact factor: 6.466
  8 in total
  2 in total

1.  Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.

Authors:  Kim R M Blenman; Michal Marczyk; Thomas Karn; Tao Qing; Xiaotong Li; Vignesh Gunasekharan; Vesal Yaghoobi; Yalai Bai; Eiman Y Ibrahim; Tristen Park; Andrea Silber; Denise M Wolf; Emily Reisenbichler; Carsten Denkert; Bruno V Sinn; Mariya Rozenblit; Julia Foldi; David L Rimm; Sibylle Loibl; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2022-06-13       Impact factor: 13.801

2.  A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

Authors:  Alexandre de Nonneville; Pascal Finetti; José Adelaide; Éric Lambaudie; Patrice Viens; Anthony Gonçalves; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.